ALX Stock Recent News
ALX LATEST HEADLINES
Here is how Alexander's (ALX) and Balfour Beatty PLC Sponsored ADR (BLFBY) have performed compared to their sector so far this year.
ALX, HMN and EBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on June 2, 2025.
WTKWY and ALX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 2, 2025.
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows:
ALX and WTKWY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 29, 2025.
ALX, ISNPY and EBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on May 29, 2025.
ALX, SPFI, BWB, NIC and WTKWY have been added to the Zacks Rank #1 (Strong Buy) List on May 29, 2025.
Here is how Alexander's (ALX) and Berkeley Group Holdings PLC Unsponsored ADR (BKGFY) have performed compared to their sector so far this year.
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.